Fox Chase Recognized by Life Sciences Pennsylvania for Pioneering New Technology in Lung Cancer Diagnosis

Combining traditional endoscopic views into the lung with computer-assisted navigation based on 3-D models of the patient’s own lung anatomy, Monarch provides physicians with continuous bronchoscopic vision throughout the entire procedure. Fox Chase was one of the first cancer centers in the nation to obtain the technology.
Combining traditional endoscopic views into the lung with computer-assisted navigation based on 3-D models of the patient’s own lung anatomy, Monarch provides physicians with continuous bronchoscopic vision throughout the entire procedure. Fox Chase was one of the first cancer centers in the nation to obtain the technology.

PHILADELPHIA (May 18, 2020)—Fox Chase Cancer Center has been named as an honoree of the Life Sciences Pennsylvania 2019 Patient Impact Award for pioneering the use of new technology that assists in earlier and more accurate diagnosis and treatment of lung nodules.

Fox Chase was recognized for its use of the Monarch Platform, a technology that features a familiar controller-like interface that physicians use to navigate a flexible robotic endoscope to the periphery of the lung. The technology improves reach, vision, and control.

 

Christopher Manley, MD
“I think some of the most important things we can do for our patients is to make our diagnosis as early and as safely as possible to get patients into treatment as quickly as possible,” said Christopher J. Manley, MD. Monarch allows him to do just this.

“I think some of the most important things we can do for our patients is to make our diagnosis as early and as safely as possible to get patients into treatment as quickly as possible,” said Christopher J. Manley, MD, an assistant professor and director of Interventional Pulmonology in the Pulmonary Medicine section. Monarch allows him to do just this.

The platform was purchased through funds raised from Fox Chase’s annual signature fundraising event, In Vino Vita. Life Sciences Pennsylvania’s Patient Impact Award recognizes a medicine, therapy, device, or organization that has made a significant contribution to the quality of health care or length of life of patients in 2019.

Combining traditional endoscopic views into the lung with computer-assisted navigation based on 3-D models of the patient’s own lung anatomy, Monarch provides physicians with continuous bronchoscopic vision throughout the entire procedure. Fox Chase was one of the first cancer centers in the nation to obtain the technology.

“Compared with traditional bronchoscopy, this new technology provides improved reach and dexterity, affording us the ability to biopsy small nodules safely,” Manley said.

Manley and Rohit Kumar, MD, director of the Respiratory and Pulmonary Function Service at Fox Chase, helped conduct the first retrospective data review of robotic bronchoscopy cases since the technology’s release in 2018.
Manley and Rohit Kumar, MD, director of the Respiratory and Pulmonary Function Service at Fox Chase, helped conduct the first retrospective data review of robotic bronchoscopy cases since the technology’s release in 2018.

Manley and Rohit Kumar, MD, director of the Respiratory and Pulmonary Function Service at Fox Chase, helped conduct the first retrospective data review of robotic bronchoscopy cases since the technology’s release in 2018. Monarch has been used in more than 250 cases to date at Fox Chase, which remains the leading robotic bronchoscopy program in the nation.

Eligible organizations for the Life Sciences Pennsylvania Patient Impact Award include medical device, diagnostic, pharmaceutical, and biotechnology companies, and research institutions with significant operations in Pennsylvania. The honorees are selected by a committee of representatives from the Pennsylvania health care and academic research community.

 

 

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text